Immunotherapy News and Research

Latest Immunotherapy News and Research

New therapy attacks the source of asthma, treats the disease at cellular level

Imagine you suffer from severe asthma, and you've tried every treatment available, but nothing has worked. You still can't breathe. Then a new therapy comes along that attacks the source of the asthma, as opposed to the symptoms, and treats the disease at a cellular level. That's the promise of biologics, and the topic of four presentations at the 2015 ACAAI Annual Scientific Meeting in San Antonio, November 5-9.

5 Nov 2015

Breastfeeding may not protect against allergies

Pregnant women and new mothers receive many messages regarding the benefits of exclusive breastfeeding for babies in the first year of life. Breastfeeding is thought to reduce the risk of allergic rhinitis (hay fever), asthma, food allergies and eczema in children.

5 Nov 2015

Many seasonal allergy sufferers take OTC products rather prescription medications

Anyone suffering with seasonal allergies knows the local pharmacy carries shelves full of over-the-counter medications to help manage symptoms. Unfortunately, most seasonal allergy sufferers take over-the counter (OTC) products rather than the treatments they actually prefer - prescription medications.

5 Nov 2015

Quad introduces MagCloudz Streptavidin Cell Separation Kit to redefine translational medical research

The most promising areas of translational medical research, including CAR-T cancer therapies and stem cell-based regenerative medicine, require the isolation and purification of large numbers of viable, functional cells.

5 Nov 2015

JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

When it comes to fending off disease and helping prevent people from falling ill, the body's immune system -- armed with T-cells that help eliminate cancer cells, virus-infected cells and more -- is second to none. But exactly how the immune system works remains, in many ways, a mystery, as there are numerous cell types whose functions and interactions with our immune systems have not been well understood.

5 Nov 2015

OncoSec signs definitive agreements to purchase $7.5 million of securities in registered direct offering

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $7.5 million of securities in a registered direct offering.

4 Nov 2015

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Pancreas cancer remains one of the deadliest cancers worldwide. In the United States, it accounts for only three percent of all diagnosed cancers but it causes almost seven percent of all cancer deaths. A pancreas cancer diagnosis often comes after age 50 and after the cancer has spread, making it difficult to remove surgically.

4 Nov 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment.

4 Nov 2015

Misleading symptoms confuse management of older patients with post-HSE relapse

Research shows that teenagers and adults with immune-mediated relapse after herpes simplex encephalitis rarely display the symptoms typically seen in children, delaying the initiation of vital immunotherapy.

3 Nov 2015

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline.

3 Nov 2015

Resistance to CD19 CAR T-cell therapy can be caused by CD19 splicing alterations

Resistance to CD19 CAR T-cell therapy, a type of immunotherapy that yields long-lasting remissions in many patients with B-cell leukemia, can be caused by CD19 splicing alterations, leading to loss of certain parts of the CD19 protein that are recognized by the CAR T cells.

31 Oct 2015

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Cervical cancer is the fourth most frequently occurring cancer in women. Human papillomavirus (HPV) is present in 99 percent of cervical cancers and is considered to be their cause. While most HPV infections will clear naturally within a few years, there has been no treatment available to hasten or improve the chance of natural eradication.

31 Oct 2015

New campaign raises awareness of City of Hope's life-saving mission and impact

Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.

31 Oct 2015

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

31 Oct 2015

Specialized type of immunotherapy can boost survival from pancreatic cancer

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from pancreatic cancer, a nearly almost-lethal disease, by more than 75 percent. The findings are so promising, human clinical trials are planned within the next year.

30 Oct 2015

Scientists one step closer to developing new treatment for inflammatory bowel disease

For patients with inflammatory bowel disease, the possibility of taking a single pill to bring long-lasting relief might seem too good to be true. Scientists at the Lewis Katz School of Medicine at Temple University are on the brink of making that happen, thanks to a recent proof-of-concept study, in which the severity of a form of inflammatory bowel disease in mice was dramatically reduced with one oral dose of a protein isolated from a bacterial biofilm.

30 Oct 2015

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

29 Oct 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Environment can make all the difference in behavior - even at the cellular level. Scientists at the Virginia Tech Carilion Research Institute have discovered even a small shift in environmental factors can change how a cell in the immune system matures.

28 Oct 2015

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

Immunotherapy treatments have proven wildly successful in treating some patients with cancer. But despite this success, the majority of patients do not respond to the treatments.

27 Oct 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

New therapy attacks the source of asthma, treats the disease at cellular level

Breastfeeding may not protect against allergies

Many seasonal allergy sufferers take OTC products rather prescription medications

Quad introduces MagCloudz Streptavidin Cell Separation Kit to redefine translational medical research

JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

OncoSec signs definitive agreements to purchase $7.5 million of securities in registered direct offering

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Misleading symptoms confuse management of older patients with post-HSE relapse

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

Resistance to CD19 CAR T-cell therapy can be caused by CD19 splicing alterations

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

New campaign raises awareness of City of Hope's life-saving mission and impact

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Specialized type of immunotherapy can boost survival from pancreatic cancer

Scientists one step closer to developing new treatment for inflammatory bowel disease

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Immunotherapy News and Research

Latest Immunotherapy News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in